Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

38,655 stories, page 314 of 645

Advanced search

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Are Peptides Safe? Potential Risks to Consider

GoodRxOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance

CancerNetworkOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Osteosarcoma ADC breakthrough sparks race as SOT106 readies trials and deals - CHOSUNBIZ

ChosunbizOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Korea pharma chiefs skip vacations to fix trials and push overseas sales - CHOSUNBIZ

ChosunbizOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

manilatimes.netOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

StockStoryOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Biotech firm Prothena's Q2 net loss narrows on lower expenses

TradingViewOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

FDA Approves Tudriqev-Nivolumab Combo for Melanoma

Oncology Nursing NewsOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Why the Orzeyful Approval Matters Beyond One Drug Class

PharmTech.comOriginal source

🇺🇸Aug 7Researchatlasventure.comTier 2 · Direct publisher

FDA approves Replimune melanoma drug previously rejected twice

Atlas VentureOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

BIOMARIN PHARMACEUTICAL ($BMRN) Releases Q2 2026 Earnings, Stock Rises

Quiver QuantitativeOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

Yahoo FinanceOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Definium Therapeutics (NASDAQ: DFTX) builds $1.1B cash war chest as Phase 3 data hit

Stock TitanOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

The Manila TimesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

The American Journal of Managed Care® (AJMC®)Original source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Insmed Catapults More Than 30%, Leading A Biotech Rally

Investor's Business DailyOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Solid Biosciences starts Duchenne Phase 3 trial; Phase 1/2 has 53 dosed

Stock TitanOriginal source

🇨🇦Aug 7Industryir.zymeworks.comTier 1 · Company source

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ZymeworksOriginal source

🇺🇸Aug 7Devicesapyxmedical.comTier 1 · Company source

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx MedicalOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TradingViewOriginal source

🌍Aug 7discoverynews.google.comTier 2 · Trade media

FDA approves Replimune melanoma drug previously rejected twice

STATOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

FDA Approves Orezeyful | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History

Yahoo! Finance CanadaOriginal source

🇺🇸Aug 7CROppd.comTier 2 · Direct publisher

REMS: To outsource or not to outsource?

Thermo Fisher PPDOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Novel mechanisms reshaping the phase 3 pipeline in wet and dry AMD | Eye Care Network - Modern Retina

Ophthalmology Times EuropeOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Tarsus to purchase Alkeus Pharmaceuticals

Glance by Eyes On EyecareOriginal source

🌍Aug 7discoverynews.google.comTier 2 · Trade media

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data

BioSpaceOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

From the lab to the boardroom: Biotech alum leads at Genentech

University of Nevada, RenoOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Relay Therapeutics earnings in spotlight amid trial progress By Investing.com

Investing.com IndiaOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Collegium Pharmaceutical Inc (COLL) (Q2 2026) Earnings Call Highlights: ADHD Portfolio Surges ...

Yahoo FinanceOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Relay Therapeutics earnings in spotlight amid trial progress By Investing.com

Investing.com UKOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Relay Therapeutics earnings in spotlight amid trial progress

Investing.comOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Tariff Update: New Section 232 Tariffs Take Effect for Certain Patented Pharmaceutical Imports

Marken.Original source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus

TipRanksOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial

TipRanksOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

Yahoo FinanceOriginal source

🌍Aug 7Associationasn-online.orgTier 2 · Direct publisher

ASN Announced as 2026 ASAE Gold Award Recipient

American Society of NephrologyOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart

MinichartOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Big Pharma Can't Merge Its Way Out Of An Innovation Problem

Life Science LeaderOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Nurix Therapeutics, Inc. (NRIX) stock price, news, quote and history

Yahoo Finance SingaporeOriginal source

🇺🇸Aug 7CROmedpace.comTier 2 · Direct publisher

Retina Development: The Next Era of Precision Therapies Is Here

MedpaceOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

FDA Inspects Two IIT Bombay Campus Canteens; Institute Says It Will Ensure Compliance

Free Press JournalOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Hillyard Technical Center Agriculture program selected for National Biotech field test

KQ2Original source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

CSPC Pharmaceutical, AstraZeneca Form Joint Venture for New Biologics Manufacturing Facility in China

biopharminternational.comOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

First mRNA flu shot gets FDA approval, raising hopes for a more effective vaccine

CIDRAPOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

America’s Next Biotech Challenge

RealClearHealthOriginal source

🌍Aug 7Industrysellaslifesciences.comTier 1 · Company source

Pipeline - Sellas Life Sciences

SELLAS Life SciencesOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Video: Pop Star Olivia Rodrigo Pushes Planned Parenthood Lie that Abortion Drug Mifepristone Is ‘Very Safe’

breitbart.comOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

CancerNetworkOriginal source

🌍Aug 7discoverynews.google.comTier 3 · Aggregated media

Merck and Gilead discontinue lung cancer drug trial

Investing.comOriginal source

🌍Aug 6discoverynews.google.comTier 3 · Aggregated media

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

PR NewswireOriginal source